Product
ADX-102
2 clinical trials
3 indications
Indication
Sjogren-Larsson SyndromeIndication
AllergyIndication
ConjunctivitisClinical trial
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)Status: Completed, Estimated PCD: 2020-01-18